Vivek K. Jayaraman Sells 26,247 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERSGet Free Report) COO Vivek K. Jayaraman sold 26,247 shares of the business’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $2.06, for a total transaction of $54,068.82. Following the completion of the sale, the chief operating officer now owns 905,447 shares of the company’s stock, valued at approximately $1,865,220.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Cerus Stock Down 3.5 %

Shares of Cerus stock opened at $1.91 on Friday. The firm’s 50 day moving average price is $2.07 and its 200-day moving average price is $1.82. The company has a quick ratio of 1.55, a current ratio of 2.14 and a debt-to-equity ratio of 1.12. Cerus Co. has a 52-week low of $1.21 and a 52-week high of $3.08. The company has a market cap of $346.24 million, a P/E ratio of -9.09 and a beta of 1.31.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on CERS shares. Stephens restated an “equal weight” rating and issued a $2.50 price target on shares of Cerus in a report on Thursday, March 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $3.00 price target on shares of Cerus in a report on Wednesday, March 6th.

Get Our Latest Report on CERS

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Sepio Capital LP grew its position in shares of Cerus by 789.1% in the 3rd quarter. Sepio Capital LP now owns 3,497,407 shares of the biotechnology company’s stock worth $5,280,000 after buying an additional 3,104,062 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Cerus by 1,878.8% in the 3rd quarter. GSA Capital Partners LLP now owns 1,292,053 shares of the biotechnology company’s stock worth $2,093,000 after buying an additional 1,226,757 shares during the last quarter. Barclays PLC grew its position in Cerus by 18.7% during the 3rd quarter. Barclays PLC now owns 1,408,323 shares of the biotechnology company’s stock worth $2,281,000 after purchasing an additional 221,859 shares during the last quarter. Algert Global LLC grew its position in Cerus by 13.6% during the 3rd quarter. Algert Global LLC now owns 593,092 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 71,020 shares during the last quarter. Finally, Swiss National Bank grew its position in Cerus by 3.7% during the 3rd quarter. Swiss National Bank now owns 396,900 shares of the biotechnology company’s stock worth $643,000 after purchasing an additional 14,000 shares during the last quarter. Hedge funds and other institutional investors own 81.72% of the company’s stock.

Cerus Company Profile

(Get Free Report)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Further Reading

Insider Buying and Selling by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.